{
    "clinical_study": {
        "@rank": "60335", 
        "arm_group": {
            "arm_group_label": "Treatment (ado-trastuzumab emtansine)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving response may continue treatment."
        }, 
        "brief_summary": {
            "textblock": "This phase I trial studies the side effects and best way of giving ado-trastuzumab emtansine\n      in treating patients with human epidermal growth factor receptor 2 (HER2)-positive\n      metastatic or locally advanced breast cancer that cannot be removed by surgery. Biological\n      therapies, such as ado-trastuzumab emtansine may stimulate the immune system in different\n      ways and stop cancer cells from growing"
        }, 
        "brief_title": "Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery", 
        "condition": [
            "HER2-positive Breast Cancer", 
            "Recurrent Breast Cancer", 
            "Stage IIIB Breast Cancer", 
            "Stage IIIC Breast Cancer", 
            "Stage IV Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To assess change in thrombokinetics (platelet circulation life span) and megakaryopoiesis\n      effects in bone marrow.\n\n      SECONDARY OBJECTIVES:\n\n      I. To evaluate the progression free survival (PFS), duration of response, benefit rate (as\n      defined by stable disease, partial response, or complete response by Response Evaluation\n      Criteria in Solid Tumors [RECIST] v 1.1), overall response rate (as defined by partial or\n      complete response by RECIST v 1.1), and survival.\n\n      II. To evaluate the safety of trastuzumab emtansine (ado-trastuzumab emtansine)\n      (non-platelet toxicity).\n\n      III. To evaluate the pharmacokinetics of trastuzumab emtansine.\n\n      OUTLINE:\n\n      Patients receive trastuzumab emtansine intravenously (IV) over 30-90 minutes on day 1.\n      Treatment repeats every 21 days for 2 courses in the absence of disease progression or\n      unacceptable toxicity. Patients achieving response may continue treatment.\n\n      After completion of study treatment, patients are followed up periodically."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed study-specific informed consent form\n\n          -  Histologically or cytologically documented breast cancer\n\n          -  Metastatic or unresectable locally advanced/recurrent breast cancer\n\n          -  HER2-positive disease documented as in situ hybridization (ISH)-positive and/or 3+by\n             immunohistochemistry (IHC) on previously collected tumor tissue\n\n          -  Absolute neutrophil count (ANC) > 1500 cells/mm^3\n\n          -  Platelet count > 100,000/mm^3\n\n          -  Hemoglobin > 9.0 g/dL (patients are allowed to receive transfused red blood cells\n             [RBC] to achieve this level)\n\n          -  Total bilirubin =< 1.5 \u00d7 upper limit of normal (ULN), except in patients with\n             previously documented Gilbert's syndrome, in which case the direct bilirubin should\n             be less than or equal to the ULN\n\n          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and\n             serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5\n             \u00d7 ULN\n\n          -  Alkaline phosphatase =< 2.5 \u00d7 ULN (patients with hepatic and/or bone metastases:\n             alkaline phosphatase =< 5 \u00d7 ULN)\n\n          -  Serum creatinine < 1.5 \u00d7 ULN\n\n          -  International normalized ratio (INR) < 1.5 \u00d7 ULN\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\n\n          -  Left ventricular ejection fraction (LVEF) >= 50% by either echocardiogram (ECHO) or\n             multigated acquisition scan (MUGA)\n\n          -  Negative results of serum pregnancy test for premenopausal women of reproductive\n             capacity and for women < 12 months after entering menopause\n\n          -  For women of childbearing potential and men with partners of childbearing potential,\n             agreement by the patient and/or partner to use a highly effective, non-hormonal form\n             of contraception or two effective forms of non-hormonal contraception\n\n          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory\n             tests, and other study procedures, including bone marrow biopsy and thrombokinetic\n             studies\n\n        Exclusion Criteria:\n\n          -  Known platelet disorder, such as von Willebrand's disease or baseline platelet count\n             of < 100,000/mm^3\n\n          -  Chemotherapy =< 21 days before first study treatment\n\n          -  Trastuzumab =< 21 days before first study treatment\n\n          -  Lapatinib =< 14 days before first study treatment\n\n          -  Investigational therapy or any other therapy =< 28 days before first study treatment\n\n          -  Any prior trastuzumab emtansine\n\n          -  Previous radiotherapy for the treatment of unresectable, locally advanced/recurrent\n             or metastatic breast cancer is not allowed if:\n\n               -  The last fraction of radiotherapy has been administered within 14 days prior to\n                  randomization\n\n               -  The patient has not recovered from any resulting acute toxicity (to grade =< 1)\n                  prior to randomization\n\n          -  Brain metastases that are untreated or symptomatic, or require any radiation,\n             surgery, or steroid therapy to control symptoms from brain metastases within 30 days\n             of first on-study thrombokinetic study; for patients with newly diagnosed brain\n             metastases or unequivocal progression of brain metastases on screening scans,\n             localized treatment (i.e., surgery, radiosurgery, and/or whole brain radiotherapy) is\n             required before study enrollment; subjects with known brain metastases must have\n             clinically controlled neurologic symptoms, defined as surgical excision and/or\n             radiation therapy followed by 14 days of stable neurologic function prior to the\n             first thrombokinetic procedure; patients with small brain metastases not symptomatic\n             and deemed requiring treatment by managing clinicians or study investigators may be\n             permitted to enroll on study\n\n          -  History of intolerance (including grade 3 or 4 infusion reaction) or hypersensitivity\n             to trastuzumab or murine proteins\n\n          -  Current peripheral neuropathy of grade >= 3 per the National Cancer Institute Common\n             Terminology Criteria for Adverse Events (NCI CTCAE) v. 4.0\n\n          -  Current unstable ventricular arrhythmia requiring treatment\n\n          -  History of symptomatic congestive heart failure (CHF) (New York Heart Association\n             [NYHA] classes II\u2212IV)\n\n          -  History of myocardial infarction or unstable angina within 6 months of enrollment\n\n          -  History of a decrease in LVEF to < 40% or symptomatic CHF with previous trastuzumab\n             treatment\n\n          -  Severe dyspnea at rest due to complications of advanced malignancy or requiring\n             current continuous oxygen therapy\n\n          -  Current severe, uncontrolled systemic disease (e.g., clinically significant\n             cardiovascular, pulmonary, or metabolic disease) resulting in a life expectancy of <\n             6 months\n\n          -  Major surgical procedure or significant traumatic injury within 28 days before\n             enrollment or anticipation of the need for major surgery during the course of study\n             treatment\n\n          -  Current pregnancy or lactation\n\n          -  Current known active infection with human immunodeficiency virus (HIV), hepatitis B,\n             and/or hepatitis C virus; for patients who are known carriers of hepatitis B virus\n             (HBV), active hepatitis B infection must be ruled out based on negative serologic\n             testing and/or determination of HBV deoxyribonucleic acid (DNA) viral load per local\n             guidelines\n\n          -  Assessed by the investigator to be unable or unwilling to comply with the\n             requirements of the protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01816035", 
            "org_study_id": "7900", 
            "secondary_id": [
                "NCI-2013-00552", 
                "P30CA015704"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (ado-trastuzumab emtansine)", 
                "description": "Given IV", 
                "intervention_name": "ado-trastuzumab emtansine", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Kadcyla", 
                    "T-DM1", 
                    "trastuzumab-DM1", 
                    "trastuzumab-MCC-DM1", 
                    "trastuzumab-MCC-DM1 antibody-drug conjugate"
                ]
            }, 
            {
                "arm_group_label": "Treatment (ado-trastuzumab emtansine)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Treatment (ado-trastuzumab emtansine)", 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Trastuzumab", 
                "Maytansine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 17, 2014", 
        "location": {
            "contact": {
                "last_name": "Vijayakrishna K. Gadi", 
                "phone": "206-288-2222"
            }, 
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98109"
                }, 
                "name": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium"
            }, 
            "investigator": {
                "last_name": "Vijayakrishna K. Gadi", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Thrombokinetic Studies of Trastuzumab Emtansine", 
        "overall_official": {
            "affiliation": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium", 
            "last_name": "Vijayakrishna Gadi", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The actual analysis will fit a linear mixed effects model, using a two-sided Wald test to compare pre-therapy to the two post-therapy values, and should have greater power than a matched pairs design. Also, platelet lifespan may be measured in absolute terms (platelet lifespan) or relative terms (percentage relative to pre-therapy lifespan), and may be transformed to decrease the influence of extreme values.", 
                "measure": "Thrombokinetic changes in the bone marrow", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to 22 days"
            }, 
            {
                "measure": "Megakaryocyte toxicity and depletion in bone marrow as assessed by NCI CTCAE v4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 42"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01816035"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence, type, and severity of adverse events (AEs) graded according to the NCI CTCAE v4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after completion of study treatment"
            }, 
            {
                "measure": "Objective response rate (ORR), based on investigator assessment using RECIST v. 1.1", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "PFS assessed using RECIST v. 1.1", 
                "safety_issue": "No", 
                "time_frame": "Time from study entry to the first occurrence of disease progression, or death from any cause, assessed up to 2 years"
            }, 
            {
                "measure": "Duration of objective response (DOR), based on investigator assessment using RECIST v.1.1", 
                "safety_issue": "No", 
                "time_frame": "First tumor assessment that supports the patient's objective response until the time of disease progression or death from any cause, assessed up to 2 years"
            }, 
            {
                "measure": "Clinical benefit rate, defined as the proportion of patients who achieve an objective response (complete response [CR] or partial response [PR]), or maintain SD for at least 6 months from study entry, based on investigator assessment using RECIST v. 1.1", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "source": "University of Washington", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Washington", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}